AtaiBeckley (ATAI) Income from Continuing Operations (2020 - 2026)
AtaiBeckley (ATAI) recorded quarterly Income from Continuing Operations of 29982000.0 in Q1 2026, down 13.29% quarter-over-quarter from 26465000.0 in Q1 2025, and down 13.29% on a YoY basis from 34577027.63 in Q1 2025.
AtaiBeckley (ATAI) Income from Continuing Operations (2020 - 2026) Analysis & Trends
AtaiBeckley has disclosed Income from Continuing Operations across 6 years of filings, most recently posting 61098000.0 for Q3 2025.
- Income from Continuing Operations for Q3 2025 came in at 61098000.0, down 132.44% year-over-year; the trailing twelve-month figure through Sep 2025 was 154656000.0 (down 22.88% YoY), and the FY2024 annual result was 148761000.0, down 288.71% from the prior year.
- Income from Continuing Operations was 29982000.0 for Q1 2026 at AtaiBeckley, down from 26465000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 26465000.0 in Q1 2025 to a low of 29982000.0 in Q1 2026.
- The 5-year median for Income from Continuing Operations is 31858000.0 (2023), against an average of 30744684.21.
- Across the five-year window, Income from Continuing Operations plunged 842.61% in 2021 and jumped 231.08% in 2023, its largest moves.
- AtaiBeckley's Income from Continuing Operations stood at 52136000.0 in 2021, then gained by 13.07% to 45323000.0 in 2022, then jumped by 63.12% to 16716000.0 in 2023, then tumbled by 135.34% to 39340000.0 in 2024, then tumbled by 55.31% to 61098000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 61098000.0 (Q3 2025), 27753000.0 (Q2 2025), and 26465000.0 (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | AtaiBeckley | 1.45 Bn | 1.45 Bn | - | -29.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.98 Mn |
| Sep 30, 2025 | -61.10 Mn |
| Jun 30, 2025 | -27.75 Mn |
| Mar 31, 2025 | -26.47 Mn |
| Mar 31, 2025 | -26.47 Mn |
| Dec 31, 2024 | -39.34 Mn |
| Sep 30, 2024 | -26.29 Mn |
| Jun 30, 2024 | -57.18 Mn |
| Mar 31, 2024 | -25.68 Mn |
| Dec 31, 2023 | -16.72 Mn |
| Sep 30, 2023 | 43.61 Mn |
| Jun 30, 2023 | -31.86 Mn |
| Mar 31, 2023 | -33.36 Mn |
| Dec 31, 2022 | -45.32 Mn |
| Sep 30, 2022 | -33.27 Mn |
| Jun 30, 2022 | -30.86 Mn |
| Mar 31, 2022 | -31.96 Mn |
| Dec 31, 2021 | -52.14 Mn |
| Sep 30, 2021 | -26.87 Mn |
| Jun 30, 2021 | -67.36 Mn |